source
- Novartis to spend $1.1 billion upfront acquiring Myricx Bio and its next-gen ADC platformNovartis announced Monday it will invest $1.1 billion in an upfront payment to acquire Myricx Bio. Myricx Bio brings an antibody-drug conjugate (ADC) payload platform that the Swiss group believes…
- Bristol Myers reports Krazati confirmatory trial fails in colorectal cancerBristol Myers Squibb disclosed that the confirmatory study of its investigational drug Krazati in combination with an EGFR inhibitor did not achieve its primary efficacy endpoints in patients with…